Navigation Links
Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Date:4/18/2008

wan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, the timing and progress of clinical studies relating to the company's transcatheter valve technologies and the market opportunity for transcatheter technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2007.

Edwards, Edwards SAPIEN and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
2. Aida Announces New Anti-Cancer Drug Under Development
3. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
4. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
9. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 DUSA Pharmaceuticals...mpany that is developing and marketing Levulan(... focused on patients with common skin conditions, ...utive Officer, will present a corporate overview a... Tuesday, November 10, 2009 at 10:00 a.m. ET at th...
(Date:11/6/2009)...6 Kaiser Foundation Health Plan, I...ir subsidiaries reported today a combined total op...nded September 30, 2009, compared to $10.2 billion...me in the third quarter was $336 million, compared.... Net non-operating income was $233 million in the...
(Date:11/6/2009)...swire-FirstCall/ -- Caraco Pharmaceutical Laborato...ac tromethamine ophthalmic solution, 0.5% followin...istration (FDA) for Sun Pharma,s Abbreviated New D...hthalmic solution on the first day following paten...eutically equivalent to Acular® Ophthalmic So...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Skin like tissue developed from human embryonic stem cells 9295 1Skin like tissue developed from human embryonic stem cells 9295 2HIMSS Electronic Health Record Association Elects New Leadership 52251 1HIMSS Electronic Health Record Association Elects New Leadership 52251 2HIMSS Electronic Health Record Association Elects New Leadership 52251 3Fujifilms New Digital X Ray System Designed to Eliminate Barriers to Digital Adoption 52246 1Fujifilms New Digital X Ray System Designed to Eliminate Barriers to Digital Adoption 52246 2Fujifilms New Digital X Ray System Designed to Eliminate Barriers to Digital Adoption 52246 3
... early non-responders unlikely to subsequently,res... may benefit,from earlier change in treatment stra...ewswire-FirstCall/,-- New data presented at the 20...h (ICOSR) suggest that antipsychotic drug,response...d,challenge the current schizophrenia treatment pa...
...Duckworth, M.D., Medical Director National,Allianc...02, 2007 /PRNewswire-USNewswire/ -- Today,the Arch...e,effectiveness of psychosocial treatments for bip...r Disorder." This is a follow up,study to one rele...edicine on the effects of antidepressants in the t...
Other Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Latest NIMH Study on Bipolar Disorder 2Latest NIMH Study on Bipolar Disorder 3
(Date:11/7/2009)... a growing problem across the U.S. , , S... students at four-year colleges do it regularly (a...g -- downing five or more alcoholic drinks at a si...lcohol as a drug," said Jenny Hwang, associate dea...r at Stony Brook University on Long Island, N.Y. I...
(Date:11/6/2009)... COM , VANCOUVER, Nov. 6 /PRNewswire-FirstCal...COM) today announced that it will report financial... 2009 on the morning of Monday, November 9, 2009. ...st at 9:00am Eastern (6:00am Pacific) on that day ...ence call, please dial 416-695-7806 or 888-789-957...
(Date:11/6/2009)...Newswire-FirstCall/ -- Centene Corporation (NYSE: ... upcoming healthcare conferences over the next few... Annual Health Care Conference, to be held Novembe...Spa in Phoenix, Centene will present Wednesday, No...and other interested parties may access Centene,s ...
(Date:11/6/2009)... Plan International, a l...fices in 66 countries around the world, has been a...health and well-being at the upcoming American Pub...p; Exposition in Philadelphia, Pennsylvania on Nov...h Association gathers organizations together to ad...
(Date:11/6/2009)...and government programs, expert says , ,...has made it more difficult than ever before for ma...ut several options are available, according to an ..., First, talk to your pharmacist, advised Carriann...sor of pharmacy practice at Butler,s College of Ph...
Breaking Medicine News(10 mins):Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2Health News:Plan's Expertise Highlighted at Premier Health Forum 2Health News: Pay Less for Prescription Drugs 2
... the Norwegian Institute of Public Health (NIPH) h...isoning in humans. Bromadiolone is a rat poison th...ases have been reported internationally where peop...previously used but due to resistance development,...
....I. [Brown University] Magnetic resonance imaging... a tumor in the body without resorting to surgery....the return signals to identify different types of ...ally helpful in locating cancerous cell clusters d...
... AMN Healthcare Services,Inc. (NYSE: AHS ), the ...cheduled to make a presentation on Thursday, June ...al Markets 2008 Healthcare Staffing Forum,taking p... company and will discuss the company,s current,op...
... 27 The Food Allergy &,Anaphylaxis Network (FAAN)... in Tarrytown, N.Y., on May 31, 2008. Many familie...in their lives. Whether attendees have,been living...or living better,while managing food allergies. To...
... WEHI have pinpointed the function of a potent can...n associated with a range of human malignancies, i... showed in 2005 that ERG is mutated in more than h...ated. , The team at WEHI has now demonstrated th...
...ommunities save time and money accepting automatic...bank accounts, PORTLAND, Ore., May 27 Vigilan an...ding provider of on-demand electronic payment,solu...ies. Communities, large or small, can utilize PayS...
Other Medicine News:Health News:Brown chemists create cancer-detecting nanoparticles 2Health News:AMN Healthcare Services to Present at the BMO Capital Markets 2008 Healthcare Staffing Forum 2Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in New York 2Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in New York 3Health News:Vigilan Offers PaySimple to Simplify Resident Billing and Collection 2
Hough Fascia Knife
Paparella Elevator Knife
Austin Duckbill Knife Elevator
Friesner Ear Knife With Protector
Medicine Products: